866-997-4948(US-Canada Toll Free)

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

Published By :

BCC Research

Published Date : Sep 2017

Category :

Biotechnology

No. of Pages : 282 Pages


The global liquid biopsy market should reach $4.5 billion by 2022 from $1.5 billion in 2017 at a compound annual growth rate (CAGR) of 24.2%, from 2017 to 2022.
The global noncancer market is expected to grow from $1.3 billion in 2017 to $2.6 billion in 2022 at a CAGR of 15.2% for the period 2017-2022.
The global cancer market is expected to grow from $229.3 million in 2017 to $1.9 billion in 2022 at a CAGR of 52.4% for the period 2017-2022.

##img_0##
Table of Contents Table of Contents Table of Contents Table of Contents Table of Contents Table of Contents
Chapter 1: Introduction ......................................................................................... 2
Study Goals and Objectives........................................................................................................................... 2
Reasons for Doing This Study ........................................................................................................................ 2
Scope of Report ............................................................................................................................................. 3
Information Sources ...................................................................................................................................... 3
Methodology ................................................................................................................................................. 3
Geographic Breakdown ................................................................................................................................. 4
Analyst's Credentials ................................................................................................................................... 10
Related BCC Research Reports.................................................................................................................... 10
Chapter 2: Summary and Highlights ..................................................................... 12
Chapter 3: Overview ............................................................................................ 16
Introduction ................................................................................................................................................ 16
Report Scope ............................................................................................................................................... 17
Liquid Biopsy versus Traditional Biopsy ...................................................................................................... 17
Markets ....................................................................................................................................................... 18
Growth Driving Forces ................................................................................................................................ 19
Key Trends ................................................................................................................................................... 20
Industry ....................................................................................................................................................... 22
Chapter 4: Technology Background .................................................................... 24
Liquid Biopsy Biomarkers ............................................................................................................................ 24
Cancer Genomics ........................................................................................................................................ 25
Noninvasive Prenatal Testing ...................................................................................................................... 29
Circulating Tumor Cell Technologies ........................................................................................................... 30
CTC Workflow ............................................................................................................................................. 31
Cell Isolation Technologies.......................................................................................................................... 31
CTC Sample Preparation Technologies ....................................................................................................... 34
CTC Downstream Analysis Technologies .................................................................................................... 35
Comparison of Liquid Biopsy with Conventional Biopsy ............................................................................ 36
Cancer Testing ......................................................................................................................................... 36
Prenatal Testing ....................................................................................................................................... 39
Chapter 5: Liquid Biopsy Initiatives ...................................................................... 43
Blood Profiling Atlas .................................................................................................................................... 44
Cambridge Single Cell Analysis Core Facility ............................................................................................... 44
Cancer-ID ..................................................................................................................................................... 44
CTCTrap Consortium ................................................................................................................................... 44
Early Cancer Detection Consortium ............................................................................................................ 45
Hematologic Oncology Consortium ............................................................................................................ 45
National Center for Single-Cell Biology ....................................................................................................... 45
Precancer Genome Atlas ............................................................................................................................. 45
Precision Medicine Initiative ....................................................................................................................... 46
Single Cell Analysis Program ....................................................................................................................... 46
TopMed ....................................................................................................................................................... 47
Worldwide Innovative Networking (WIN) Consortium ............................................................................... 47
Chapter 6: Liquid Biopsy Applications .................................................................. 49
Introduction ................................................................................................................................................ 49
Cancer Applications .................................................................................................................................... 49
Precision Medicine .................................................................................................................................. 49
Cancer Biomarker Status ......................................................................................................................... 51
Cancer Market Segments ........................................................................................................................ 52
Reproductive Health Applications .............................................................................................................. 54
Transplant Diagnostics Applications ........................................................................................................... 56
Chapter 7: Liquid Biopsy Industry ........................................................................ 58
Introduction ................................................................................................................................................ 58
NGS Instrument Industry ............................................................................................................................ 59
Third-Generation Sequencing Industry ....................................................................................................... 63
Droplet Digital PCR Industry ....................................................................................................................... 66
Target Enrichment and Amplification Industry ........................................................................................... 68
Single-Cell DNA Polymerase Industry ......................................................................................................... 69
NGS Clinical Informatics Industry ................................................................................................................ 71
Testing Services Industry ............................................................................................................................ 73
Noninvasive Prenatal Testing Industry ....................................................................................................... 78
Fetal Cell NIPT Industry ............................................................................................................................... 84
CTC Capture and Detection Industry .......................................................................................................... 85
Liquid Biopsy Industry ................................................................................................................................. 88
Direct-to-Consumer Genetic Testing Industry ............................................................................................ 98
Chapter 8: Acquisitions and Strategic Alliances ................................................. 102
Acquisitions ............................................................................................................................................... 102
Strategic Alliances ..................................................................................................................................... 106
Trends .................................................................................................................................................... 111
2016 Alliances ........................................................................................................................................ 112
2017 Alliances ........................................................................................................................................ 117
Chapter 9: Liquid Biopsy Markets ...................................................................... 123
Growth Driving Forces .............................................................................................................................. 123
Liquid Biopsy Market by Indication........................................................................................................... 125
Liquid Biopsy Market by Biomarker Type ................................................................................................. 127
Liquid Biopsy Market by Analysis Platform ............................................................................................... 128
Liquid Biopsy Market by Analysis Purpose ............................................................................................... 128
Noninvasive Prenatal Testing Market ....................................................................................................... 130
Cancer Markets ......................................................................................................................................... 135
Cancer Market by Indication ................................................................................................................. 135
Cancer Market by Analysis Purpose ...................................................................................................... 145
Cancer Market by Biomarker Class ....................................................................................................... 153
Cancer Market by Analysis Method ...................................................................................................... 155
Breast Cancer Market ............................................................................................................................ 158
Colorectal Cancer Market...................................................................................................................... 159
Hematological Cancer Market ............................................................................................................... 160
Lung Cancer Market .............................................................................................................................. 161
Pan-Cancer Market ................................................................................................................................ 162
Transplant Markets ................................................................................................................................... 163
Geographical Market ................................................................................................................................ 167
Chapter 10: Patent Review ................................................................................ 175
Circulating Tumor Cell Patents.................................................................................................................. 175
Cell-Free DNA Patents ........................................................................................................................... 176
Liquid Biopsy- and Sequencing-Related Patent Issues ............................................................................. 176
Chapter 11: Company Profiles ........................................................................... 181
About BCC Research ......................................................................................... 292
About BCC Research.................................................................................................................................. 293
BCC Membership ...................................................................................................................................... 293
BCC Custom Research ............................................................................................................................... 293

List of Table

List of Tables
Summary Table: Global Liquid Biopsy Market, by Disease Class, Through 2022 ($ Millions) ................... 12
Table 1 Liquid Biopsy Sample Types .......................................................................................................... 16
Table 2 Liquid Biopsy Report Scope ........................................................................................................... 17
Table 3 Global Liquid Biopsy Market, by Analysis Type, Through 2022 ($ Millions) .................................. 18
Table 4 Growth Driving Forces ................................................................................................................... 19
Table 5 Key Trends in Liquid Biopsy Market .............................................................................................. 20
Table 6 Liquid Biopsy Industry Subsectors .................................................................................................. 22
Table 7 Liquid Biopsy Biomarker Classes .................................................................................................... 24
Table 8 Single-Cell Analysis to Identify Cancer Driver Mutations ............................................................... 27
Table 9 Genomics-Based Oncology Workflow ............................................................................................ 28
Table 10 Unique Challenges of CTC Capture and Analysis.......................................................................... 30
Table 11 CTC Workflow ............................................................................................................................... 31
Table 12 Cell Differentiators ....................................................................................................................... 32
Table 13 Cell Isolation Technologies ........................................................................................................... 33
Table 14 CTC Sample Preparation Technologies ........................................................................................ 34
Table 15 Single-Cell Analysis Technologies ................................................................................................. 35
Table 16 Estimated Annual Solid Biopsy Procedures Performed in the U.S. for Selected Cancers ........... 37
Table 17 Main Risks for Needle-Based Tissue Biopsies .............................................................................. 37
Table 18 Factors in Tissue Biopsy................................................................................................................ 38
Table 19 Prenatal Invasive Testing Technologies ....................................................................................... 39
Table 20 Invasive versus Noninvasive Prenatal Technologies .................................................................... 40
Table 21 Key Liquid Biopsy Research and Development Programs ............................................................ 43
Table 22 Source of Foreign Biomarkers for Liquid Biopsy Applications ..................................................... 49
Table 23 Personalized Medicine Driven by Cancer Common Genetic Mutations ...................................... 50
Table 24 Cancer Liquid Biopsy Biomarker Clinical Status ........................................................................... 51
Table 25 Cancer Liquid Biopsy Market Segments ....................................................................................... 52
Table 26 Reproductive Health Screening Application ................................................................................ 54
Table 27 Ethical Issues Associated with NIPT ............................................................................................. 55
Table 28 Transplant Diagnostics Application .............................................................................................. 56
Table 29 Key Segments within the Liquid Biopsy Industry ......................................................................... 58
Table 30 Next-Generation Sequencing Instrument Companies ................................................................. 60
Table 31 3GS Industry, by Tier Status ......................................................................................................... 63
Table 32 Advantages of Droplet Digital PCR for Single-Cell Analysis .......................................................... 66
Table 33 Droplet Digital PCR Industry ......................................................................................................... 67
Table 34 Target Enrichment Industry......................................................................................................... 68
Table 35 Single-Cell DNA Polymerase Industry ........................................................................................... 70
Table 36 Next-Generation Sequencing Clinical Informatics Company Positioning .................................... 71
Table 37 Selected NGS Clinical Testing Laboratories .................................................................................. 73
Table 38 NIPT Industry ............................................................................................................................... 78
Table 39 Global Market Share for NIPT, by Company and by Region, 2017 ............................................... 80
Table 40 German NGS-based Noninvasive Prenatal Diagnostic Companies, 2017 ................................... 81
Table 41 NIPT Test Licensing, by Country .................................................................................................. 83
Table 42 Fetal Cell NIPT Industry ................................................................................................................ 84
Table 43 CTC Capture and Detection Industry ............................................................................................ 86
Table 44 Liquid Biopsy Industry Company Focus ........................................................................................ 89
Table 45 Example of NGS-based Liquid Biopsy Market Differentiation ..................................................... 97
Table 46 Key Competitors in the Direct-to-Consumer Genetic Testing Industry ....................................... 98
Table 47 Liquid Biopsy Industry Acquisitions, January 2016July 2017 ................................................... 102
Table 48 Liquid Biopsy Strategic Alliances, January 2016July 2017 ........................................................ 106
Table 49 Liquid Biopsy Key Growth Driving Forces ................................................................................... 123
Table 50 Global Liquid Biopsy Market, by Indication, Through 2022 ($ Millions) ................................... 125
Table 51 Global Liquid Biopsy Market, by Biomarker Type, Through 2022 ($ Millions)........................... 127
Table 52 Global Liquid Biopsy Market, by Analysis Platform, Through 2022 ($ Millions) ........................ 128
Table 53 Global Liquid Biopsy Market, by Analysis Purpose, Through 2022 ($ Millions) ........................ 129
Table 54 Global NIPT Market, by Analysis Purpose, Through 2022 ($ Millions) ...................................... 130
Table 55 Global NIPT Market, by Risk Type, Through 2022 ($ Millions) ................................................... 131
Table 56 Global NIPT Market, by Biomarker Class, Through 2022 ($ Millions) ....................................... 133
Table 57 Global NIPT Market, by Analysis Method, Through 2022 ($ Millions) ...................................... 133
Table 58 Limitations of Solid Biopsy in Cancer Applications .................................................................... 135
Table 59 Global Cancer Market, by Indication, Through 2022 ($ Millions) ............................................. 136
Table 60 Five-Year Survival Rate for Ovarian Cancer (%) ......................................................................... 139
Table 61 Prostate Cancer Testing Industry ............................................................................................... 143
Table 62 Molecular Thyroid Nodule Classifier Test Company Positioning ............................................... 144
Table 63 Global Cancer Market, by Analysis Purpose, Through 2022 ($ Millions) .................................. 145
Table 64 Cancer Detection Methods ........................................................................................................ 146
Table 65 Early Detection Tissue of Origin Approaches ............................................................................. 147
Table 66 NGS Instrument Company Companion Diagnostics Status ........................................................ 149
Table 67 Global Cancer Market, by Biomarker Class, Through 2022 ($ Millions).................................... 153
Table 68 Global Cancer Market, by Analysis Method, Through 2022 ($ Millions) .................................. 155
Table 69 Global Breast Cancer Market, by Analysis Method, Through 2022 ($ Millions) ....................... 158
Table 70 Global Colorectal Cancer Market, by Analysis Method, Through 2022 ($ Millions) ................. 159
Table 71 Global Hematological Cancer Market, by Analysis Method, Through 2022 ($ Millions) .......... 160
Table 72 Global Lung Cancer Market, by Analysis Method, Through 2022 ($ Millions) .......................... 161
Table 73 Global Pan-Cancer Market, by Analysis Method, Through 2022 ($ Millions) ........................... 162
Table 74 Global Liquid Biopsy Transplant Market, by Analysis Purpose, Through 2022 ($ Millions) ...... 163
Table 75 Global Liquid Biopsy Transplant Market, by Organ Type, Through 2022 ($ Millions) .............. 164
Table 76 Transplant Procedures Performed in the U.S., 2015 and 2016 ................................................. 165
Table 77 Global Liquid Biopsy Transplant Market, by Analysis Method, Through 2022 ($ Millions) ...... 166
Table 78 Global Liquid Biopsy Transplant Market, by Biomarker Class, Through 2022 ($ Millions) ....... 166
Table 79 Global Liquid Biopsy Market, by Region, Through 2022 ($ Millions) ........................................ 168
Table 80 Global Cancer Liquid Biopsy Market, by Region, Through 2022 ($ Millions) ............................. 169
Table 81 Global NIPT Market, by Region, Through 2022 ($ Millions) ...................................................... 171
Table 82 Global Transplant Market, by Region, Through 2022 ($ Millions) ............................................ 172
Table 83 CTC-Related Patents, by Region, 20072017 ............................................................................. 175
Table 84 Cell-Free DNA-Related Patents, by Region, 20072017............................................................. 176
Table 85 Status of Liquid Biopsy and Sequencing-Related Patent Disputes ............................................. 177
Table 86 Sensitivity to Detect Drug-resistant Mutations in Viruses (%) ................................................... 262

List of Chart

List of Figures
Summary Figure: Global Liquid Biopsy Market, by Disease Class, 2015-2022 ($ Millions) ...................... 13
Figure 1 How Cancer Genomics Drives Liquid Biopsy ................................................................................. 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *